Share this article on:

CONTRIBUTORS

doi: 10.1212/01.CON.0000526046.43919.09
Contributors

Kerry H. Levin, MD, FAAN, Guest Editor

Chairman, Department of Neurology; Director, Neuromuscular Center; Professor of Neurology, Cleveland Clinic, Cleveland, Ohio

aDr Levin serves as neurology director of the American Board of Psychiatry and Neurology and on the editorial board of Muscle & Nerve. Dr Levin receives publishing royalties from Elsevier and UpToDate Inc.

bDr Levin reports no disclosure.

Jeffrey A. Allen, MD

Associate Professor of Neurology, University of Minnesota, Minneapolis, Minnesota

aDr Allen serves on the global medical advisory board of the GBC/CIDP Foundation International, on the organizing committee of the Inflammatory Neuropathy Consortium, and as a consultant for CSL Behring and Grifols. Dr Allen receives research/grant support from CSL Behring and has received personal compensation for speaking engagements from Grifols.

bDr Allen discusses the unlabeled/investigational use of alemtuzumab, azathioprine, bevacizumab, chlorambucil, cyclophosphamide, cyclosporine, fludarabine, interferon beta-1a, lenalidomide, melphalan, methotrexate, mycophenolate mofetil, rituximab, tacrolimus, and thalidomide for the treatment of chronic demyelinating polyneuropathies.

Peter D. Donofrio, MD, FAAN

Professor of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee

aDr Donofrio has served on the editorial board of Muscle & Nerve and receives publishing royalties from Demos Medical Publishing. Dr Donofrio serves as consultant for and has received personal compensation for speaking engagements for CSL Behring and Grifols.

bDr Donofrio reports no disclosure.

Stephen A. Goutman, MD, MS

Assistant Professor of Neurology, University of Michigan, Ann Arbor, Michigan

aDr Goutman has consulted for Cytokinetics, Inc, and has received research/grant support from the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention; the ALS Association; the National Institutes of Health/National Institute of Environmental Health Sciences (K23ES027221); Neuralstem, Inc; and Target ALS.

bDr Goutman discusses the unlabeled/investigational use of amitriptyline, atropine, botulinium toxin, citalopram, and mexiletine for the symptomatic management of amyotrophic lateral sclerosis.

Raghav Govindarajan, MD, FISQua, FACSc, FCPP, FASA, MAcadMEd, FAAN

Assistant Professor of Clinical Neurology, ALS Association/Muscular Dystrophy Association Clinic Director, Clerkship Director, Associate Medical Director, Director of Patient Safety and Quality Improvement, University of Missouri, Columbia, Missouri

aDr Govindarajan serves as president elect of the Boone County Medical Society, on the neurologist advisory board of Abbvie Inc, and as an associate editor of Frontiers in Neurology. Dr Govindarajan receives research/grant support from the ALS Association and publishing royalties from Springer Nature.

Kelly Graham Gwathmey, MD

Assistant Professor of Neurology, Muscular Dystrophy Association Clinic Director, University of Virginia, Charlottesville, Virginia

a,bDr Gwathmey reports no disclosures.

Bashar Katirji, MD, FACP, FAAN

Director of Neuromuscular Center, Director of EMG Laboratory, University Hospitals Cleveland Medical Center; Professor of Neurology, Case Western Reserve University, Cleveland, Ohio

aDr Katirji receives publishing royalties from the American Association of Neuromuscular & Electrodiagnostic Medicine, Elsevier, and Springer Nature.

bDr Katirji reports no disclosure.

John C. Kincaid, MD, FAAN

Kenneth L. and Selma G. Earnest Professor of Neurology, Indiana School of Medicine, Indianapolis, Indiana

aDr Kincaid has provided expert medical testimony in neurologic legal cases for Social Security administrative law judges and has received research/grant support from Ionis Pharmaceuticals, Inc. Dr Kincaid receives publishing royalties from Wolters Kluwer and Demos Medical Publishing.

bDr Kincaid reports no disclosure.

Yuebing Li, MD, PhD

Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio

aDr Li reports no disclosure.

bDr Li discusses the unlabeled/investigational use of tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, and voltage-gated calcium channel ligands for the treatment of painful polyneuropathy and the unlabeled/investigational use of diflunisal and tafamidis for familial amyloid polyneuropathy.

Sindhu Ramchandren, MD, MS

Assistant Professor of Neurology; Director, Muscular Dystrophy Association Care Center Clinic and Charcot-Marie-Tooth Center of Excellence Clinic, University of Michigan, Ann Arbor, Michigan

aDr Ramchandren has served on advisory boards for Biogen and Sarepta Therapeutics, Inc, and has received research/grant support from the Muscular Dystrophy Association (Foundation Clinic Grant) and the National Institutes of Health (K23 NS072279).

bDr Ramchandren reports no disclosure.

James A. Russell, DO, FAAN

Director, Curt & Shonda Schilling ALS Clinic, Lahey Hospital & Medical Center, Burlington, Massachusetts; Clinical Professor of Neurology, Tufts University School of Medicine, Boston, Massachusetts

aDr Russell has served as a consultant for W2O Group, receives publishing royalties from McGraw-Hill Education, and has received personal compensation for medicolegal record review.

bDr Russell reports no disclosure.

Komal Sawlani, MD

Neurologist, Neuromuscular Center, University Hospitals Cleveland Medical Center; Clinical Instructor, Case Western Reserve University School of Medicine, Cleveland, Ohio

a,bDr Sawlani reports no disclosures.

Zachary Simmons, MD, FAAN

Professor, Departments of Neurology and Humanities, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

aDr Simmons serves as editor-in-chief of Muscle & Nerve and as a consultant for Cytokinetics, Inc, and Neuralstem, Inc. Dr Simmons receives research/grant support from the ALS Association; Biogen; Cytokinetics, Inc; and GlaxoSmithKline plc.

bDr Simmons discusses the controversies surrounding legislation to permit access to therapies not yet approved by the US Food and Drug Administration.

Jinny O. Tavee, MD

Associate Professor, Neuromuscular Division Medical Director, Northwestern University Feinberg School of Medicine, Chicago, Illinois

aDr Tavee has received personal compensation for speaking engagements from Mallinckrodt Pharmaceuticals and grant/research support for work in clinical trials from Araim Pharmaceuticals, Inc.

bDr Tavee discusses the unlabeled/investigational use of ARA 290 for the treatment of sarcoidosis and IVIg for the treatment of paraneoplastic disease, sarcoidosis neuropathy, neuropathy related to monoclonal gammopathy, celiac-related neuropathy, and other autoimmune neuropathies.

Nimish J. Thakore, MD, DM

Neurologist, Neuromuscular Center, Department of Neurology, Cleveland Clinic; Assistant Professor, Department of Medicine, Case Western Reserve University, Cleveland Ohio

aDr Thakore reports no disclosure.

bDr Thakore discusses the unlabeled/investigational use of subcutaneous immunoglobulin and mycophenolate mofetil for the treatment of multifocal motor neuropathy.

Francis O. Walker, MD, FAAN

Professor of Neurology, Wake Forest University Medical School, Winston-Salem, North Carolina

aDr Walker serves on the editorial boards of the Journal of Clinical Neurophysiology and Muscle & Nerve and has received personal compensation for speaking engagements for Grifols. Dr Walker has received research/grant support from CHDI, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and Vaccinex Inc and receives publishing royalties from Elsevier and UpToDate, Inc. Dr Walker has provided expert legal testimony on botulinum toxin indications.

bDr Walker reports no disclosure.

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

aDr Gelb receives royalties from Oxford University Press and UpToDate, Inc.

bDr Gelb reports no disclosure.

Adam Kelly, MD

Associate Professor of Neurology, University of Rochester Medical Center; Chief of Neurology, Highland Hospital, Rochester, New York

aDr Kelly has received research support from the Donald W. Reynolds Foundation.

bDr Kelly reports no disclosure.

© 2017 American Academy of Neurology